Novel targeted therapies for eosinophilic disorders Michael E. Wechsler, MD, MMSc, Patricia C. Fulkerson, MD, PhD, Bruce S. Bochner, MD, Gail M. Gauvreau, PhD, Gerald J. Gleich, MD, Tim Henkel, MD, PhD, Roland Kolbeck, PhD, Sameer K. Mathur, MD, PhD, Hector Ortega, MD, ScD, Jatin Patel, MD, Calman Prussin, MD, Paolo Renzi, MD, Marc E. Rothenberg, MD, PhD, Florence Roufosse, MD, PhD, Dagmar Simon, MD, Hans-Uwe Simon, MD, PhD, Andrew Wardlaw, MD, Peter F. Weller, MD, Amy D. Klion, MD  Journal of Allergy and Clinical Immunology  Volume 130, Issue 3, Pages 563-571 (September 2012) DOI: 10.1016/j.jaci.2012.07.027 Copyright © 2012 Terms and Conditions

Fig 1 Active and theoretic eosinophil-selective therapeutic targets. The eosinophil possesses multiple targets that are the focus of active research in patients with hypereosinophilic diseases. These include IL-5, CCR3, Siglec-8, EMR1, CRTH2, cysteinyl leukotriene 1 (CYSLTR1), and the glucocorticoid receptor (GR). Multiple other targets on the eosinophil and in pathways indirectly related to the eosinophil exist and are not depicted in this image. Medical Illustrator Jacqueline Schaffer provided this work. Journal of Allergy and Clinical Immunology 2012 130, 563-571DOI: (10.1016/j.jaci.2012.07.027) Copyright © 2012 Terms and Conditions